The content on this site is intended for healthcare professionals only
Prof Cheng-Har Yip spoke to ecancer at the BGICC 2020 conference in Cairo, Egypt about DCIS (ductal carcinoma in situ).
She describes firstly what DCIS is; a pre-cancerous or non-invasive cancerous lesion of the breast, classified as Stage 0.
Prof Yip explains why and when a mastectomy might be needed, and some of the genomics research currently used to look at which DCIS may progress.
She also outlines what some of the risks and complications can be along these procedures.
Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy
Advancing breast cancer treatment in Uganda by improving molecular testing
The advantages of IORT for early breast cancer treatment
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Global adoption of single-shot targeted IORT for breast cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
